open access

Vol 12, No 3 (2017)
Review Papers
Published online: 2017-06-30
Get Citation

Patient with arterial hypertension and hypercholesterolaemia — can we be more effective in treatment?

Iwona Gorczyca-Michta, Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2017.0053
·
Folia Cardiologica 2017;12(3):262-270.

open access

Vol 12, No 3 (2017)
Review Papers
Published online: 2017-06-30

Abstract

Arterial hypertension and dyslipidemia are the most common cardiovascular risk factors that often coexist. The effectiveness of their treatment is still unsatisfactory. The use of combination antihypertensive and hypolipemic therapy improves outcomes for the treatment of arterial hypertension and hypercholesterolaemia.

Abstract

Arterial hypertension and dyslipidemia are the most common cardiovascular risk factors that often coexist. The effectiveness of their treatment is still unsatisfactory. The use of combination antihypertensive and hypolipemic therapy improves outcomes for the treatment of arterial hypertension and hypercholesterolaemia.

Get Citation

Keywords

hypertension, dyslipidemia, combination therapy

About this article
Title

Patient with arterial hypertension and hypercholesterolaemia — can we be more effective in treatment?

Journal

Folia Cardiologica

Issue

Vol 12, No 3 (2017)

Pages

262-270

Published online

2017-06-30

DOI

10.5603/FC.2017.0053

Bibliographic record

Folia Cardiologica 2017;12(3):262-270.

Keywords

hypertension
dyslipidemia
combination therapy

Authors

Iwona Gorczyca-Michta
Beata Wożakowska-Kapłon

References (27)
  1. Sulicka J, Fornal M, Gryglewska B, et al. Selected cardiovascular risk factors in primary care patients. Arterial Hypertens. 2006; 10: 370–376.
  2. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2011 update: a report from the American Heart Association. Circulation. 2011; 123(4): e18–e209.
  3. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 — BHS IV. J Hum Hypertens. 2004; 18(3): 139–185.
  4. Zdrojewski T, Bandosz P, Rutkowski M, et al. Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętni ­czego w Polsce — wyniki badania NATPOL 2011. Nadciś Tętn. 2014; 18: 116–117.
  5. Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B, et al. Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. Kardiol Pol. 2005; 63(supl. 4).
  6. Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation. 2003; 107(17): 2185–2189.
  7. Scheidt-Nave CC, Busch MA, Knopf H, et al. [Prevalence of dyslipidemia among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS 1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013; 56(5–6): 661–667.
  8. Zdrojewski T, Solnica B, Cybulska B, et al. Rozpowszechnienie zaburzeń lipidowych w Polsce. Wyniki badania NATPOL 2011. Kardio Pol. 2016; 74(3): 213–223.
  9. Thoenes M, Bramlage P, Zhong S, et al. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract. 2012; 2012: 925046.
  10. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147–1152.
  11. Tykarski A, Narkiewicz K, Gaciong Z, et al. Zasady postępowania w nadciśnieniu tętniczym — 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciś Tętn Prakt 2015; 1: 1-70. 2015; 1(1): 1–7/.
  12. Wożakowska-Kapłon B, Filipiak K, Mamcarz A, et al. Aktualne problemy terapii dyslipidemii w Polsce — II Deklaracja Sopocka. Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol Pol. 2014; 72(9): 847–853.
  13. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005; 365(9457): 434–441.
  14. Ferdinand K. KC. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease. Curr Med Res Opin. 2005; 21: 1091–1097.
  15. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004; 25(6): 484–491.
  16. Welch V, Tang SSK. Treatment and control of BP and lipids in patients with hypertension and additional risk factors. Am J Cardiovasc Drugs. 2007; 7(5): 381–389.
  17. Zdrojewski T, Bandosz P, Szpakowski P. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL-PLUS. In: Szpakowski P. ed. Postępy w nefrologii i nadciśnieniu tętniczym. Vol. II. Medycyna Praktyczna, Kraków 2002: 11–15.
  18. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940–2948.
  19. Byrd JB, Zeng C, Tavel HM, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J. 2011; 162(2): 340–346.
  20. de Cates AN, Farr MR, Wright N, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014(4): CD009868.
  21. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895–906.
  22. Bertrand ME, Ferrari R, Remme WJ, et al. EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010; 159(5): 795–802.
  23. Hatala R, Pella D, Hatalová K, et al. Optimization of blood pressure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertension. Clin Drug Investig. 2012; 32(9): 603–612.
  24. Fujita M, Yamazaki T, Hayashi D, et al. JCAD Study Investigators. Comparison of cardiovascular events in patients with angiographically documented coronary narrowing with combined renin-angiotensin system inhibitor plus statin versus renin-angiotensin system inhibitor alone versus statin alone (from the Japanese Coronary Artery Disease Study). Am J Cardiol. 2007; 100(12): 1750–1753.
  25. Sever P, Dahlöf B, Poulter N, et al. ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006; 27(24): 2982–2988.
  26. Sirenko Y, Radchenko G. PERSPECTIVA Study Group. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High Blood Press Cardiovasc Prev. 2017; 24(1): 85–93.
  27. Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011; 124(2): 128–135.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl